In the Boardroom
Refine search
Biotechnology
Sweden’s Hansa Biopharma announced today the appointment of Adam Cutler as chief financial officer (CFO) and a member of the executive committee, effective June 22, 2026. 15 June 2026
Pharmaceutical
Canada-based clinical-stage drug developer ZYUS Life Sciences Corporation yesterday announced a strategic realignment of its corporate structure and leadership to strengthen its focus on the Company's core clinical development priorities. 12 June 2026
Biotechnology
Spanish women’s health biotech company Oriva Therapeutics has appointed Agnès Arbat as chief executive, as it advances a pipeline of treatments for chronic gynecological diseases led by the Phase I endometriosis candidate ORV-362. 11 June 2026
Biotechnology
UK biotech PhoreMost today announced its lead program, PMC-001, a next-generation, small molecule microtubule targeting agent (MTA) for primary and secondary brain cancers. 10 June 2026
Biotechnology
German biotech CatalYm has appointed Peter Garcia as chief financial officer, adding a seasoned life sciences finance executive as its lead asset, visugromab, moves through a broad mid- to late-stage clinical program. 10 June 2026
Biotechnology
Swedish rare diseases company Hansa Biopharma today announced that Fredrik Röök has been appointed as vice president business development effective August 17. 10 June 2026
Pharmaceutical
Australia’s clinical-stage radiopharma company today announced the appointment of Justyna Kelly as chief technology officer (CTO) and François Gaudet as chief scientific officer (CSO), expanding the company’s executive leadership team in the USA as it continues to scale its US capabilities, and advance its growing pipeline of innovative targeted alpha therapies. 8 June 2026
Biotechnology
US biotech Cocrystal Pharma has appointed James Sapirstein as its chief executive (CEO), effective immediately. 3 June 2026
Pharmaceutical
US clinical-stage pharma Altesa BioSciences has appointed Brett Haumann to its board and Gwen Skloot as senior vice president of clinical development, adding respiratory drug development experience as it advances vapendavir in chronic obstructive pulmonary disease (COPD). 3 June 2026
Biotechnology
US late-stage cell therapy developer ProKidney has announced the appointment of Kenneth Locke as chief technical officer. 3 June 2026
Biotechnology
Australian oncology-focused biotech Kazia Therapeutics today announced the appointment of James Levine as chief financial officer (CFO), effective June 1, 2026. Mr Levine brings more than two decades of experience across investment banking, executive and financial leadership at publicly traded biotech companies. 2 June 2026
Biotechnology
German biotech FundaMental Pharma has appointed Hans Eriksson as chief medical officer, bringing in a depression drug development veteran as it prepares IND-enabling studies for its lead preclinical candidate, FMP374. 2 June 2026
Biotechnology
US biotech Capricor Therapeutics just named Michael Maurer as Chief Commercial Officer as the company heads toward an August 22 PDUFA date for deramiocel, its cell therapy for Duchenne muscular dystrophy. 30 May 2026
Pharmaceutical
Swiss clinical-stage biotech Topadur has appointed Felix Ehrat and Peter Jager to its board of directors, adding senior legal, governance and pharmaceutical industry experience as the company prepares for its next stage of growth. 28 May 2026
Biotechnology
US biotech Immunic today announced the appointment of distinguished biopharmaceutical executive Erik Lundgren as chief executive (CEO), effective May 22, 2026, with employment beginning on June 1, 2026. 27 May 2026
Generics
The UK subsidiary of German generics, biosimilars and consumer healthcare major STADA Arzneimittel is investing a seven-figure sum in an expanded, state-of-the-art commercial office in Green Park, Reading, as it advances its ambition of establishing the business as a British consumer healthcare and pharmaceutical powerhouse. 27 May 2026
Pharmaceutical
Jeffery Taubenberger, the acting director of the US National Institute of Allergy and Infectious Diseases (NIAID), has stepped down from the role, according to reports citing congressional Democrats and sources familiar with the matter. 22 May 2026
Pharmaceutical
US clinical research services company Precision for Medicine has hired former US Food and Drug Administration oncology official Paz Vellanki as vice president of clinical development, oncology, strengthening the group’s regulatory advisory capabilities as cancer drug development becomes more complicated. 22 May 2026
Pharmaceutical
Family-controlled Italian drugmaker Chiesi Group has announced a planned leadership transition, appointing Maria Paola Chiesi as chair of its board of directors, succeeding Alessandro Chiesi, who will become vice chair. 20 May 2026
Biotechnology
US allogeneic NK cell therapies developer Artiva Biotherapeutics announced the appointment of Dr Diego Miralles as president and head of research and development. 20 May 2026
Pharmaceutical
Spanish plasma-derived medicines company Grifols today announced the appointment of Tomás Dagá, Grifols’ board member, as vice president of the board of Grifols Egypt for Plasma Derivatives (GEPD), the joint venture created together with the Government of Egypt to deploy the country’s first comprehensive plasma ecosystem, and the first in Africa and the Middle East. 27 November 2025
Pharmaceutical
Neurizon has appointed Justine Conway, global head of business development at US animal-health group Elanco, as board observer, further tightening the companies’ partnership. She will join all board and committee meetings without voting rights, bringing long-running transaction and strategy experience from roles in Sydney, London and New York. 26 November 2025
Pharmaceutical
Specialty pharma company SERB Pharmaceuticals has revealed the appointment of Vignesh Rajah as its chief medical officer (CMO). 19 November 2025
Biotechnology
Privately-held UK oncology company Mosaic Therapeutics has announced the appointment of Stephen Shuttleworth as chief scientific officer (CSO). 17 November 2025
Biotechnology
Australian clinical-stage radiopharmaceutical company AdvanCell today announced the appointment of Philina Lee as chief executive (CEO) and a member of the board of directors. 17 November 2025
Biotechnology
US medtech firm Terumo Blood and Cell Technologies has appointed Liza Loidolt as general manager of its cell and gene therapy business, marking a sharper strategic push into advanced therapeutics. Parent company Terumo Corporation recently reported annual revenue of about $6.1 billion, with growth in blood-and-cell technologies. 14 November 2025
Pharmaceutical
Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, has announced the appointment of Carlos Martin as chief commercial officer (CCO). 14 November 2025
Generics
German generics and consumer healthcare major STADA Arzneimittel has appointed Craig Shaw as its general manager in the UK. 14 November 2025
Pharmaceutical
UK-based specialty CNS-focused pharma company CNX Therapeutics has appointed Kevan Leggett as chairman to support its growth strategy, effective November 3, 2025. 13 November 2025
Biotechnology
LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, and other neuropsychiatric diseases, today announced the appointment of Kaya Pai Panandiker as chief commercial officer (CCO). 12 November 2025
Pharmaceutical
The US Department of Health and Human Services (HHS) and the Food and Drug Administration (FDA) today announced that Dr Richard Pazdur, has been appointed director of the Center for Drug Evaluation and Research (CDER). 12 November 2025
Biotechnology
US contract development and manufacturing organization Avid Bioservices appointed Dave Stewart as chief technology and transformation officer, a newly created position that signals the company’s next growth phase under chief executive Kenneth Bilenberg. 11 November 2025
Pharmaceutical
US immunology specialist Celldex has appointed Teri Lawver as senior vice president, chief commercial officer. 11 November 2025
Pharmaceutical
Belgian biopharma company UCB has announced a leadership reshuffle, effective January 1, 2026, as part of a plan to reinforce cross-functional collaboration and sustain growth. 7 November 2025
Biotechnology
US mRNA-based therapeutics company Strand Therapeutics has announced the promotion of Prashant Nambiar to chief scientific officer and appointment of Ethan Cash as senior vice president, head of portfolio management and program development. 6 November 2025
Pharmaceutical
UK biotech Slingshot Therapeutics, part of the Syncona Accelerator, has expanded its senior team with the appointments of John Isaac as chief scientific officer and Bobby Soni as chief business officer. The move supports the company’s strategy to advance early-stage academic research into drug candidates ready for clinical development. 4 November 2025
Biotechnology
SOTIO Biotech, a Czech clinical-stage biopharma owned by PPF Group, today announced the promotion of Dr Vivi Boura, an accomplished oncologist with extensive experience leading the clinical development of novel cancer therapies, to chief medical officer (CMO). 4 November 2025
Biotechnology
UK-based neuropsychiatry company Draig Therapeutics has announced the appointment of Ivana Magovčević-Liebisch as president and chief executive. 3 November 2025
Pharmaceutical
Irish healthcare group Uniphar has unified its US businesses under one banner, rebranding RRD Biopharma Development, Uniphar Clinical, Diligent Health Solutions and BESTMSLs as Uniphar Pharma Services US. The move consolidates the company’s clinical, medical and commercial operations across New York, North Carolina, Washington DC and Mississippi. 3 November 2025
Pharmaceutical
Austrian biotech VALANX Biotech has appointed Klaus Orlinger as chief scientific officer, reinforcing its leadership as the company advances its first antibody-drug conjugate (ADC), VLX-ADC-001, toward candidate selection. The move signals VALANX’s shift from technology development to therapeutic application of its GoldenSite platform. 30 October 2025
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze